Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC
Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021.
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time, will launch history’s first large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, pain, stress, and anxiety. These unprecedented Radicle Discovery studies will involve more than 10,000 participants and are set to kick off in early 2022.
Radicle Science closed out 2021 with the ground-breaking completion of 25 randomized controlled trials (RCTs) of cannabinoid products, including history’s largest CBD RCT. The Radicle Real World Evidence (RWE) studies, involving over 7,000 participants, examined various formulations of CBD-containing products and their effect on key health outcomes across five domains including general well-being, quality of life, sleep quality, pain, and feelings of stress and anxiety.
RADICLE SCIENCE BREAKS NEW GROUND IN FIRST HALF OF 2022
Radicle Discovery: Looking forward and making history
In the first half of 2022, Radicle Science will continue to conduct rigorous clinical trials on CBD products for pain, sleep disturbance, stress, and anxiety, while also commencing history’s first blinded, randomized, placebo-controlled clinical trials on rare cannabinoids for various conditions such as:
- Effect of CBG on stress, anxiety, pain, and sleep disturbance
- Effect of CBC on pain, anxiety, and sleep disturbance
- Effect of CBN on sleep disturbance, stress, anxiety, and pain
- Effect of THCV on energy, focus, and appetite
Brands participating in various portions of the clinical trials include Columbia Care, Lord Jones, Open Book Extracts, Straight Hemp, Trokie®, and Wana Brands.
Co-founder and CEO of Radicle Science, Dr. Jeff Chen, MD/MBA, explains; “We are headed for exponential growth in 2022 as we prepare to study ten times more people than we did in 2021.”
People from diverse backgrounds, demographics, and ages are encouraged to sign up to participate in a Radicle study and be a part of history.
Radicle Science speaks: Sharing insights with the industry
Radicle Science is excited to share knowledge with consumers, regulators, manufacturers, and healthcare providers from the aggregate anonymized data across our studies and to join conversations surrounding the future of cannabinoid clinical research.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?